Look Towards A New Future

Feb 15, 2012

Immunomodulators Market to 2017 - Immunosuppressant Antibodies to Replace Antimetabolites as the Highest Value Sector by 2017

Immunosuppressants generated revenues of $92.2 billion in 2010 while immunostimulants generated revenues of $53.7 billion. There are more classes of immunosuppressants than immunostimulants because it is difficult to boost the cells of the immune system as they all respond to antigens in different ways. The immunostimulants market is estimated to grow at a Compound Annual Growth Rate (CAGR) of 10.5% and the immunosuppressants market is forecast to grow at a CAGR of 7.3%, although there are more products in the pipeline for immunosuppressants. Immunostimulatory Monoclonal Antibodies (mAbs) such as cancer antibodies and vaccines will contribute most to the growth of the markets as there is a great deal of scope for these classes in the oncology market, valued at $60.5 billion in 2010.

Antimetabolic Drugs Generated the Highest Revenues of all Classes of Immunomodulators

Antiproliferative and antimetabolic drugs generated revenues of approximately $33.2 billion in 2010. However, with the gradual approval of mAbs as first-line treatment, antiproliferative and antimetabolic drugs will grow at a comparatively slow rate. Conventional therapy, namely chemotherapy, has a long history of poor safety profiles due to systemic action characteristics, which means its often fails to impart the desired effect at the site of action. Cancer is better managed with personalized oncological treatments such as measuring erbB2 (erythroblastic leukemia viral oncogene homolog 2) and EGFR (Epidermal Growth Factor Receptor) proteins in breast, lung and colorectal cancer patients before selecting suitable treatments. Herceptin is used in the treatment of women with breast cancer in which HER2 (Human Epidermal growth factor Receptor 2) protein is overexpressed.

Immunomodulators Market

Published: February 2012
No. of Pages: 290
Price : Single User License - US$3500

This report provides insight about immunomodulators sales forecasts until 2017. Immunomodulators markets in the key geographies of the US, Europe and other relevant regions are also covered in the report, as are immunomodulators R&D pipelines. The report provides in-depth analysis and market forecasts of the major drug classes, which include immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, and antimetabolites), and immunostimulants (antibodies, interferon alpha and vaccines). The report also explores the competitive landscape, with a competitive analysis of the top companies in the market.

  • Data and analysis of the immunomodulators market in the leading geographies of the US and Europe. Different drug classes of immunomodulators discussed in the report are immunosuppressants (antibodies, interferon beta, glucocorticoids, calcineurin inhibitors, antimetabolites) and immunostimulants (antibodies, interferon alpha and vaccines).
  • Annualized market data for the immunomodulators market from 2002 to 2010, with forecasts to 2017.
  • Market data on the geographical landscape and therapeutic landscape, including market sizes, market shares, annual costs of therapy and sales volumes
  • Key drivers and restraints that have had significant impact on the market.
  • Competitive landscape of the global immunomodulators market including benchmarking of the top companies. The key companies studied in this report are Hoffman La Roche, Amgen, Abbott, Johnson & Johnson, Novartis, Biogen Idec, Merck, Bristol-Myers Squibb, Eli Lilly.
Reasons to buy
  • Build effective strategies to launch pipeline products, by identifying potential geographies.
  • Exploit in-licensing and out-licensing opportunities by identifying products to fill their portfolio gaps.
  • Develop key strategic initiatives by studying the key strategies of the top competitors.
  • Develop market-entry and market expansion strategies, by identifying the geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms which can produce first–in-class molecules with improved efficacy and safety profiles.